— Know what they know.
Not Investment Advice

GBT NASDAQ

Global Blood Therapeutics, Inc.
1W: +0.5% 1M: +1.0% 3M: +104.5% 1Y: +162.2% 3Y: +39.8% 5Y: +120.9%
$68.49
Last traded 2022-10-04 — delisted
NASDAQ · Healthcare · Biotechnology

Cash Flow Trends

Operating Cash Flow
-$257M -21.2% ▼
Capital Expenditures
$3M +63.1% ▲
5Y CAGR: +19.0%
Free Cash Flow
-$260M -17.9% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$190M -1.4% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2017FY2018FY2019FY2020FY2021
— Operating Activities —
Net Income-$117M-$174M-$267M-$248M-$303M
Depreciation & Amort.$2M$5M$10M$11M$9M
Stock-Based Comp.$14M$30M$46M$71M$79M
Change in Working Capital$8M$5M$27M-$47M-$42M
Other Non-Cash Items$704K-$616K-$10M$658K$1M
Operating Cash Flow-$93M-$135M-$194M-$212M-$257M
— Investing Activities —
Capital Expenditures-$3M-$5M-$3M-$9M-$3M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$128M-$361M-$435M-$58M-$50M
Investment Sales$96M$182M$361M$384M$66M
Other Investing-$1M$75K$45K$0$0
Investing Cash Flow-$36M-$184M-$77M$317M$12M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased-$421K-$12K$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$235M$398M$298M$87M$434M
Financing Cash Flow$235M$398M$298M$87M$434M
Net Change in Cash$106M$78M$27M$193M$190M
Cash End of Period$198M$278M$305M$497M$687M
Free Cash Flow-$96M-$140M-$198M-$221M-$260M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms